Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Squamous Intraepithelial Lesions 4Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Vaginal Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Squamous Cell Cancer 1HIV Seropositivity 1Anal Canal Carcinoma 1

Interventions

Fluorouracil 3Radiotherapy 2Cisplatin 2Cetuximab 2rocakinogene sifuplasmid 1durvalumab 1VGX-3100 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Mitomycin 1Magnetic Resonance Spectroscopy 1MEDI0457 1Ipilimumab 1Immunoglobulin G 1Disulfides 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anal Canal Carcinoma × VGX-3100 × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡